Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550793 | 1.00 | GABRR1 (0.37) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL13448432 | 0.83 | — | — | |
| SCHEMBL13448433 | 0.83 | — | — | |
| SCHEMBL17147639 | 0.81 | — | — | |
| SCHEMBL13448111 | 0.79 | SLC1A3 (0.39) | — | |
| SCHEMBL13761744 | 0.78 | SMN1; SMN2 (0.33) | ALDH1A1 | |
| SCHEMBL4550792 | 0.78 | SMN1; SMN2 (0.33) | ALDH1A1 | |
| SCHEMBL15452092 | 0.76 | APAF1 (0.39) | ALDH1A1APAF1POLB | |
| SCHEMBL18656597 | 0.76 | APAF1 (0.39) | ALDH1A1APAF1POLB | |
| SCHEMBL19273823 | 0.76 | APAF1 (0.39) | ALDH1A1APAF1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| WO-2017040606-A1 | ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2016115090-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2015196071-A9 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-8168648-B2 | Camptothecin derivatives and uses thereof | TAIWAN LIPOSOME CO., LTD. (TW) | 2012-05-01 | — | — | US | disclosed |
| US-20100227877-A1 | NEW CAMPTOTHECIN DERIVATIVES AND USES THEREOF | TAIWAN LIPOSOME CO. LTD. (TW) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227877-A1 | NEW CAMPTOTHECIN DERIVATIVES AND USES THEREOF | LDHA, LDHB, TOP2A | GABRR1 3137/4885CYP1A2 2660/4885FOLH1 561/4885 |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | GABRR1 986/4885CYP1A2 4799/4885FOLH1 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.